Shilpa Medicare has successfully completed inspection carried out by the United States Food and Drug Administration (USFDA) at its formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India with one minor observation. The inspection was carried out between July 24 and July 28, 2017.
The company is in the process of submission of corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
